Drug design, development and therapy · 2025
Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhan Ruanjuan, Shen Yuxin, Fu Haoxin, Wu Hualu, Chen Xiaohai, Yu Yige, Xu Ren-Ai
Аннотация
BACKGROUND: Baricitinib is widely used as a selective Janus kinase (JAK) inhibitor for the treatment of immune-mediated inflammatory diseases in clinic. It is now successfully applied in reducing inflammation and suppressing COVID-19-associated immune dysregulation. As knowledge of the appropriate plasma level of baricitinib in COVID-19 patients is deficient, the measurement of the level of baricitinib in plasma during treatment is necessary and important.
PURPOSE: The aim of this study was to establish a bioanalytical method to detect the concentration of baricitinib in COVID-19 patients' plasma by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
METHODS: The preparation process of the injected sample was to spike 100 μL of plasma and 10 μL of internal standard (IS, upadacitinib) working solution, then add 1:3 of acetonitrile to obtain the supernatant. The intra-day and inter-day precision and accuracy, matrix effect, recovery, and stability of the established methodology were all required.
RESULTS: The method was established to determine the plasma levels in 22 COVID-19 patients. After taking 2 mg/day or 4 mg/day of baricitinib, the mean plasma concentrations of the patients were 15.36 ng/mL and 12.64 ng/mL, respectively.
CONCLUSION: This novel UPLC-MS/MS method enables rapid and accurate determination of baricitinib concentrations in human plasma, which is suitable for the therapeutic drug monitoring (TDM) of baricitinib.
PURPOSE: The aim of this study was to establish a bioanalytical method to detect the concentration of baricitinib in COVID-19 patients' plasma by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
METHODS: The preparation process of the injected sample was to spike 100 μL of plasma and 10 μL of internal standard (IS, upadacitinib) working solution, then add 1:3 of acetonitrile to obtain the supernatant. The intra-day and inter-day precision and accuracy, matrix effect, recovery, and stability of the established methodology were all required.
RESULTS: The method was established to determine the plasma levels in 22 COVID-19 patients. After taking 2 mg/day or 4 mg/day of baricitinib, the mean plasma concentrations of the patients were 15.36 ng/mL and 12.64 ng/mL, respectively.
CONCLUSION: This novel UPLC-MS/MS method enables rapid and accurate determination of baricitinib concentrations in human plasma, which is suitable for the therapeutic drug monitoring (TDM) of baricitinib.